MeSH term
Frequency | Condition_Probility | Adult | 137 | 0.0 |
Blood Glucose/metabolism | 2 | 0.0 |
Humans | 732 | 0.0 |
Incidence | 3 | 0.0 |
Male | 490 | 0.0 |
Middle Aged | 144 | 0.0 |
Reference Values | 11 | 0.0 |
Risk Factors | 13 | 0.0 |
Albumins/metabolism | 2 | 1.0 |
Animals | 232 | 0.0 |
Immunohistochemistry | 70 | 0.0 |
Meningioma/*metabolism/pathology | 2 | 11.0 |
Prognosis | 28 | 0.0 |
Recurrence | 5 | 0.0 |
Time Factors | 30 | 0.0 |
United States | 2 | 0.0 |
Calcimycin/pharmacology | 4 | 1.0 |
English Abstract | 29 | 0.0 |
Infertility, Male/*diagnosis | 2 | 66.0 |
Ionophores/pharmacology | 4 | 2.0 |
Research Support, Non-U.S. Gov't | 408 | 0.0 |
Terbutaline/pharmacology | 2 | 50.0 |
Androgen Antagonists/*pharmacology | 9 | 42.0 |
Anilides/pharmacology | 12 | 46.0 |
Antineoplastic Agents/*pharmacology | 5 | 0.0 |
DNA Primers/chemistry | 5 | 0.0 |
Enzyme Inhibitors/pharmacology | 15 | 0.0 |
Flavonoids/pharmacology | 5 | 1.0 |
Flutamide/*analogs & derivatives/pharmacology | 7 | 87.0 |
Interleukin-6/*pharmacology | 3 | 1.0 |
Prostatic Neoplasms/*drug therapy/metabolism | 3 | 25.0 |
Receptors, Androgen/*metabolism | 71 | 62.0 |
Reverse Transcriptase Polymerase Chain Reaction | 37 | 0.0 |
Signal Transduction/drug effects | 4 | 0.0 |
Transfection | 108 | 0.0 |
Tumor Cells, Cultured/drug effects/metabolism | 4 | 2.0 |
Androgens/pharmacology | 9 | 18.0 |
Cell Division/drug effects | 20 | 0.0 |
Cell Nucleus | 2 | 2.0 |
Comparative Study | 69 | 0.0 |
Electrophoretic Mobility Shift Assay | 4 | 0.0 |
Prostate-Specific Antigen/genetics/metabolism | 2 | 50.0 |
Prostatic Neoplasms/*pathology | 10 | 8.0 |
Receptors, Androgen/genetics/metabolism | 6 | 42.0 |
Testosterone/*pharmacology | 5 | 16.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Up-Regulation | 9 | 0.0 |
Aged | 118 | 0.0 |
Aged, 80 and over | 55 | 0.0 |
Analysis of Variance | 7 | 0.0 |
Base Sequence | 64 | 0.0 |
Cohort Studies | 3 | 0.0 |
Genotype | 18 | 0.0 |
Molecular Sequence Data | 82 | 0.0 |
Polymerase Chain Reaction | 25 | 0.0 |
*Polymorphism, Genetic | 17 | 0.0 |
Probability | 3 | 0.0 |
Prospective Studies | 10 | 0.0 |
Receptors, Androgen/*analysis | 52 | 80.0 |
Sensitivity and Specificity | 11 | 0.0 |
Tumor Markers, Biological/*analysis | 7 | 0.0 |
Aging/metabolism | 2 | 1.0 |
Cell Nucleus/metabolism/pathology | 3 | 9.0 |
Female | 231 | 0.0 |
Linear Models | 2 | 0.0 |
Receptors, Androgen/analysis/*biosynthesis | 4 | 100.0 |
Sex Factors | 7 | 0.0 |
Amino Acid Sequence | 61 | 0.0 |
Binding Sites | 43 | 0.0 |
Cells, Cultured | 36 | 0.0 |
Histone Deacetylases/metabolism | 2 | 2.0 |
Mammals | 4 | 1.0 |
Mutation | 44 | 0.0 |
Nuclear Proteins/genetics/*metabolism | 2 | 0.0 |
Receptors, Androgen/drug effects/*genetics/metabolism | 5 | 83.0 |
Repressor Proteins/genetics/*metabolism | 3 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 240 | 0.0 |
Transcription, Genetic | 44 | 0.0 |
Two-Hybrid System Techniques | 18 | 1.0 |
Prostatic Neoplasms/*genetics | 7 | 4.0 |
Receptors, Androgen/*genetics | 67 | 64.0 |
*Transcription, Genetic | 20 | 1.0 |
Trinucleotide Repeats/genetics | 5 | 8.0 |
Disease Progression | 14 | 0.0 |
Genetic Predisposition to Disease | 5 | 0.0 |
Receptors, Androgen/genetics/*metabolism | 29 | 63.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 66 | 0.0 |
Androgen Antagonists/*therapeutic use | 9 | 24.0 |
*Mutation | 19 | 0.0 |
Point Mutation | 14 | 0.0 |
Tumor Cells, Cultured | 122 | 0.0 |
Androgens/physiology | 9 | 21.0 |
Cell Line | 77 | 0.0 |
Gene Expression Regulation | 14 | 0.0 |
Immunoenzyme Techniques | 27 | 0.0 |
Mice | 60 | 0.0 |
Receptors, Androgen/physiology | 3 | 37.0 |
*Repressor Proteins | 2 | 0.0 |
*Sex Characteristics | 2 | 1.0 |
Androgen Antagonists/pharmacology | 17 | 48.0 |
Androgens/*pharmacology | 11 | 20.0 |
Brain/metabolism | 3 | 0.0 |
Dihydrotestosterone/pharmacology | 28 | 36.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Receptors, Androgen/metabolism | 9 | 21.0 |
Testosterone/blood/pharmacology | 2 | 50.0 |
Biological Assay | 3 | 1.0 |
Endocrine System/drug effects | 3 | 30.0 |
Forecasting | 4 | 1.0 |
Ligands | 58 | 2.0 |
Receptors, Androgen/*drug effects/physiology | 3 | 100.0 |
Structure-Activity Relationship | 30 | 1.0 |
Cell Nucleus/*metabolism | 4 | 0.0 |
Chromones/pharmacology | 3 | 1.0 |
Cytoskeletal Proteins/*metabolism | 3 | 1.0 |
Glycogen Synthase Kinase 3 | 2 | 2.0 |
Morpholines/pharmacology | 3 | 1.0 |
*Protein-Serine-Threonine Kinases | 5 | 0.0 |
Trans-Activators/*metabolism | 6 | 0.0 |
COS Cells | 31 | 1.0 |
Hela Cells | 23 | 0.0 |
Protein Binding | 41 | 0.0 |
SUMO-1 Protein/*metabolism | 3 | 10.0 |
Transcription, Genetic/physiology | 3 | 1.0 |
Cercopithecus aethiops | 16 | 1.0 |
DNA, Complementary | 4 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Gene Expression Regulation/*physiology | 4 | 1.0 |
Genes, Reporter | 39 | 1.0 |
*Nuclear Proteins | 4 | 0.0 |
Recombinant Proteins/metabolism | 5 | 0.0 |
Sequence Alignment | 5 | 0.0 |
Transcription Factors/*metabolism | 4 | 0.0 |
beta-Galactosidase/genetics | 2 | 1.0 |
Dihydrotestosterone/*pharmacology | 9 | 28.0 |
Receptors, Androgen/drug effects/*metabolism | 8 | 88.0 |
Androgens/deficiency/*physiology | 3 | 60.0 |
*Gene Expression Profiling | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 13 | 0.0 |
Mice, Nude | 17 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Prostatic Neoplasms/*genetics/metabolism | 7 | 20.0 |
Transplantation, Heterologous | 8 | 0.0 |
Androgens/metabolism | 15 | 24.0 |
Cell Line, Tumor | 26 | 0.0 |
Nucleic Acid Conformation | 3 | 0.0 |
Prostatic Neoplasms/epidemiology/*genetics | 2 | 15.0 |
RNA Stability | 2 | 3.0 |
Receptors, Androgen/*genetics/metabolism | 22 | 73.0 |
Repetitive Sequences, Nucleic Acid | 10 | 1.0 |
Chromatography, Affinity | 4 | 0.0 |
Epidermal Growth Factor/pharmacology | 3 | 0.0 |
Forskolin/pharmacology | 2 | 0.0 |
Kinetics | 28 | 0.0 |
MAP Kinase Signaling System | 4 | 1.0 |
Mass Fragmentography | 2 | 0.0 |
Mutagenesis, Site-Directed | 16 | 0.0 |
Peptides/chemistry | 2 | 0.0 |
Phosphorylation | 26 | 0.0 |
Plasmids/metabolism | 18 | 1.0 |
Prostatic Neoplasms/*metabolism | 21 | 17.0 |
Serine/chemistry | 2 | 1.0 |
Signal Transduction | 29 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
Anilides/*pharmacology | 2 | 66.0 |
Prostate-Specific Antigen/biosynthesis | 3 | 23.0 |
Prostatic Neoplasms/genetics/metabolism | 5 | 38.0 |
Rabbits | 10 | 0.0 |
Receptors, Androgen/*antagonists & inhibitors/genetics | 2 | 100.0 |
Recombinant Fusion Proteins/genetics/metabolism | 10 | 0.0 |
Transcription Factors/genetics/metabolism | 3 | 0.0 |
Transcription, Genetic/*drug effects | 3 | 0.0 |
Signal Transduction/drug effects/physiology | 2 | 0.0 |
Genes, p53/genetics | 3 | 1.0 |
Neoplasm Staging | 13 | 0.0 |
Receptors, Androgen/*biosynthesis | 12 | 63.0 |
Receptors, Estrogen/biosynthesis | 3 | 6.0 |
Receptors, Progesterone/biosynthesis | 3 | 9.0 |
Down-Regulation/drug effects | 4 | 1.0 |
Neoplasm Transplantation | 15 | 1.0 |
Receptors, Androgen/*drug effects/metabolism | 4 | 100.0 |
Treatment Outcome | 6 | 0.0 |
Xenograft Model Antitumor Assays | 3 | 1.0 |
Amino Acid Motifs | 8 | 0.0 |
Enhancer Elements (Genetics) | 2 | 0.0 |
Promoter Regions (Genetics) | 26 | 0.0 |
Receptors, Androgen/chemistry/genetics/*metabolism | 6 | 85.0 |
Sequence Homology, Amino Acid | 13 | 0.0 |
Trans-Activation (Genetics) | 54 | 3.0 |
Adenosine Monophosphate/*diagnostic use | 2 | 100.0 |
Bronchial Provocation Tests | 3 | 4.0 |
Bronchoconstriction/*drug effects | 3 | 33.0 |
Cross-Over Studies | 2 | 0.0 |
Dose-Response Relationship, Drug | 30 | 0.0 |
Double-Blind Method | 4 | 0.0 |
Acetylation | 5 | 0.0 |
Acetyltransferases/*metabolism | 2 | 2.0 |
Down-Regulation | 13 | 0.0 |
Prostatic Neoplasms/metabolism | 12 | 23.0 |
Cell Nucleus/chemistry | 11 | 6.0 |
Consensus Sequence | 4 | 0.0 |
DNA/metabolism | 9 | 0.0 |
DNA-Binding Proteins/metabolism | 6 | 0.0 |
Gene Expression | 15 | 0.0 |
*Gene Expression Regulation | 5 | 0.0 |
Mammary Tumor Virus, Mouse/genetics | 9 | 23.0 |
Oocytes/metabolism | 3 | 1.0 |
RNA, Messenger/genetics | 9 | 0.0 |
Receptors, Androgen/antagonists & inhibitors/genetics/*physiology | 2 | 100.0 |
Response Elements | 4 | 1.0 |
Terminal Repeat Sequences | 2 | 6.0 |
Xenopus laevis | 3 | 0.0 |
Apoptosis/drug effects/*physiology | 2 | 0.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
Enzyme Inhibitors/metabolism | 3 | 1.0 |
Hydroxamic Acids/metabolism | 2 | 18.0 |
In Vitro | 23 | 0.0 |
*MAP Kinase Kinase Kinase 1 | 2 | 1.0 |
Protein-Serine-Threonine Kinases/*metabolism | 3 | 0.0 |
*Trans-Activation (Genetics) | 15 | 1.0 |
Trans-Activators/genetics/metabolism | 2 | 1.0 |
Alleles | 14 | 0.0 |
Case-Control Studies | 13 | 0.0 |
Italy | 2 | 0.0 |
Ovarian Neoplasms/*genetics | 4 | 1.0 |
*Trinucleotide Repeats | 4 | 3.0 |
Receptors, Androgen/*physiology | 16 | 55.0 |
Signal Transduction/physiology | 6 | 0.0 |
Transcription Factors/physiology | 2 | 0.0 |
European Continental Ancestry Group | 3 | 0.0 |
Linkage (Genetics) | 6 | 0.0 |
CHO Cells | 14 | 0.0 |
Fibroblasts/metabolism | 13 | 1.0 |
Hamsters | 18 | 0.0 |
Models, Chemical | 2 | 0.0 |
Radioligand Assay | 14 | 3.0 |
Rats | 65 | 0.0 |
Receptor, Adenosine A2A | 5 | 31.0 |
Receptors, Glucocorticoid/*physiology | 2 | 14.0 |
Trans-Activation (Genetics)/drug effects | 5 | 2.0 |
Chromosomes, Human, Pair 5 | 2 | 1.0 |
Cytoskeletal Proteins/metabolism | 2 | 0.0 |
DNA Mutational Analysis | 8 | 0.0 |
Liver Neoplasms/*metabolism/pathology | 2 | 2.0 |
Loss of Heterozygosity | 2 | 0.0 |
Microsatellite Repeats | 3 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 4 | 0.0 |
Receptors, Steroid/*metabolism | 8 | 14.0 |
*Signal Transduction | 5 | 0.0 |
*Trans-Activators | 2 | 0.0 |
*Zebrafish Proteins | 2 | 0.0 |
Aging/*physiology | 3 | 1.0 |
Alkaline Phosphatase/blood | 2 | 1.0 |
Cross-Sectional Studies | 2 | 0.0 |
Estradiol/blood | 2 | 0.0 |
Luteinizing Hormone/blood | 5 | 0.0 |
Sequence Analysis, DNA | 6 | 0.0 |
Sex Hormone-Binding Globulin/analysis | 2 | 0.0 |
Testosterone/*blood | 3 | 1.0 |
Trinucleotide Repeats/*genetics | 14 | 18.0 |
Antibiotics, Antineoplastic/*pharmacology | 2 | 1.0 |
Gene Expression/drug effects | 9 | 1.0 |
Prostate-Specific Antigen/genetics | 11 | 52.0 |
*Prostatic Neoplasms | 2 | 14.0 |
RNA, Messenger/analysis | 17 | 0.0 |
Receptors, Androgen/*genetics/*metabolism | 10 | 83.0 |
Blotting, Western | 47 | 0.0 |
Cell Division | 27 | 0.0 |
Chromosome Aberrations | 4 | 0.0 |
Mice, SCID | 6 | 0.0 |
Phenotype | 27 | 0.0 |
Prostatic Neoplasms/*genetics/pathology | 5 | 6.0 |
Receptors, Androgen/analysis | 9 | 31.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/metabolism | 3 | 3.0 |
Cell Survival/drug effects | 2 | 0.0 |
Androgens/*metabolism | 13 | 22.0 |
Prostate/*physiology | 2 | 20.0 |
DNA Primers | 14 | 0.0 |
Adenoviridae/genetics | 3 | 0.0 |
Dexamethasone/pharmacology | 6 | 1.0 |
Glucocorticoids/pharmacology | 3 | 2.0 |
Luciferases/drug effects/genetics/metabolism | 2 | 20.0 |
Pesticides/pharmacology | 2 | 66.0 |
Progesterone/pharmacology | 9 | 7.0 |
Promoter Regions (Genetics)/genetics | 6 | 0.0 |
Receptors, Androgen/agonists/antagonists & inhibitors/*metabolism | 3 | 100.0 |
Receptors, Glucocorticoid/agonists/antagonists & inhibitors/*metabolism | 2 | 100.0 |
Recombinant Fusion Proteins/drug effects/genetics/metabolism | 2 | 10.0 |
Transfection/methods | 2 | 1.0 |
Estradiol/pharmacology | 8 | 3.0 |
Estrogen Antagonists/pharmacology | 4 | 4.0 |
Molecular Structure | 9 | 1.0 |
Plasmids/genetics | 4 | 0.0 |
Breast Neoplasms/*genetics | 4 | 0.0 |
Polymorphism, Genetic | 12 | 0.0 |
Aneuploidy | 2 | 1.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Flow Cytometry | 7 | 0.0 |
Fluorescent Antibody Technique, Indirect | 4 | 0.0 |
Paraffin Embedding | 10 | 3.0 |
Prostatic Neoplasms/genetics/*metabolism/pathology | 5 | 20.0 |
Gene Therapy | 2 | 0.0 |
In Situ Nick-End Labeling | 2 | 0.0 |
Ki-67 Antigen/metabolism | 4 | 1.0 |
Prostate-Specific Antigen/metabolism | 6 | 17.0 |
Prostatic Neoplasms/metabolism/pathology/*therapy | 2 | 66.0 |
RNA, Messenger/metabolism | 24 | 0.0 |
Active Transport, Cell Nucleus | 6 | 2.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 2 | 0.0 |
Metribolone/metabolism | 8 | 53.0 |
Gene Library | 4 | 0.0 |
Prostate/metabolism | 11 | 14.0 |
Recombinant Fusion Proteins/metabolism | 11 | 0.0 |
Testosterone 5-alpha-Reductase/*metabolism | 3 | 60.0 |
Tissue Distribution | 8 | 0.0 |
Breast Neoplasms/*metabolism/pathology | 5 | 2.0 |
Cell Differentiation | 4 | 0.0 |
Neoplasm Proteins/metabolism | 3 | 0.0 |
Receptors, Estrogen/metabolism | 11 | 3.0 |
Receptors, Progesterone/metabolism | 14 | 7.0 |
Tumor Markers, Biological/*metabolism | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 17 | 0.0 |
Indoles/pharmacology | 2 | 0.0 |
RNA, Small Interfering/genetics | 2 | 1.0 |
Gene Expression Regulation/drug effects/physiology | 2 | 3.0 |
Testis/physiology | 3 | 8.0 |
Cell Nucleus/metabolism | 21 | 1.0 |
Muscle, Skeletal/metabolism | 2 | 1.0 |
Protein Structure, Tertiary | 24 | 0.0 |
Receptors, Androgen/chemistry/*genetics/*metabolism | 2 | 100.0 |
Recombinant Fusion Proteins/chemistry/genetics/metabolism | 2 | 1.0 |
Adolescent | 32 | 0.0 |
Pedigree | 11 | 0.0 |
Receptors, Androgen/chemistry/*genetics/metabolism | 2 | 100.0 |
Androgen-Insensitivity Syndrome/*genetics/metabolism | 2 | 100.0 |
Immunoblotting | 13 | 0.0 |
Open Reading Frames | 2 | 0.0 |
Glutathione Transferase/metabolism | 9 | 1.0 |
Cloning, Molecular | 16 | 0.0 |
Estrogen Receptor alpha | 6 | 2.0 |
Organ Specificity | 5 | 0.0 |
Antineoplastic Agents, Hormonal/therapeutic use | 2 | 4.0 |
Cyclin E/*physiology | 2 | 28.0 |
Receptors, Androgen/genetics/*physiology | 9 | 90.0 |
Blotting, Northern | 16 | 0.0 |
DNA, Complementary/metabolism | 5 | 0.0 |
Dogs | 8 | 0.0 |
Luciferases/metabolism | 8 | 1.0 |
Myocardium/metabolism | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Testis/metabolism | 3 | 1.0 |
*Androgens | 4 | 40.0 |
Epithelial Cells/metabolism | 5 | 1.0 |
In Situ Hybridization | 7 | 0.0 |
Neoplasm Proteins/*biosynthesis/genetics | 2 | 1.0 |
Neoplasms, Hormone-Dependent/genetics/*metabolism/pathology | 3 | 42.0 |
Prostate-Specific Antigen/blood | 6 | 6.0 |
Prostatic Hyperplasia/metabolism | 5 | 15.0 |
RNA, Messenger/biosynthesis/genetics | 5 | 0.0 |
*Transcription Factors | 11 | 0.0 |
Tumor Markers, Biological/blood | 2 | 1.0 |
Anilides/*therapeutic use | 2 | 33.0 |
Combined Modality Therapy | 2 | 0.0 |
Neoplasm Recurrence, Local | 6 | 1.0 |
Prostatic Neoplasms/*genetics/*therapy | 2 | 100.0 |
Androgens/*physiology | 9 | 20.0 |
Calcium Channel Blockers/pharmacology | 3 | 3.0 |
Progesterone/*physiology | 2 | 11.0 |
Tyrosine/metabolism | 2 | 0.0 |
Japan | 2 | 0.0 |
Depression, Chemical | 2 | 1.0 |
Histone Deacetylases/antagonists & inhibitors | 2 | 4.0 |
Hydroxamic Acids/pharmacology | 4 | 2.0 |
Molecular Weight | 5 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Enzyme Activation | 9 | 0.0 |
Genes, Dominant | 2 | 0.0 |
Models, Biological | 12 | 0.0 |
Precipitin Tests | 14 | 0.0 |
RNA, Neoplasm/analysis | 3 | 1.0 |
Receptors, Androgen/*biosynthesis/genetics | 9 | 90.0 |
Retrospective Studies | 13 | 0.0 |
Survival Analysis | 7 | 0.0 |
Androstenedione/metabolism | 2 | 6.0 |
Ovary/*metabolism | 2 | 3.0 |
Progesterone/metabolism | 2 | 2.0 |
Receptors, Androgen/antagonists & inhibitors/*metabolism | 3 | 60.0 |
Postmenopause | 5 | 2.0 |
Receptors, Androgen/drug effects/metabolism | 2 | 33.0 |
Binding Sites/genetics | 5 | 0.0 |
Gene Expression Regulation/*drug effects | 4 | 0.0 |
Promoter Regions (Genetics)/drug effects | 2 | 1.0 |
Histone Deacetylases/antagonists & inhibitors/metabolism | 2 | 11.0 |
Receptors, Androgen/drug effects/genetics/*metabolism | 4 | 80.0 |
Antineoplastic Agents, Hormonal/*therapeutic use | 3 | 4.0 |
In Situ Hybridization, Fluorescence/methods | 2 | 2.0 |
Prostatic Neoplasms/*drug therapy | 3 | 8.0 |
X Chromosome/genetics | 3 | 1.0 |
Prostate-Specific Antigen/*blood | 2 | 2.0 |
Sex Hormone-Binding Globulin/*metabolism | 3 | 1.0 |
*Intracellular Signaling Peptides and Proteins | 5 | 0.0 |
Biopsy, Needle | 3 | 0.0 |
Predictive Value of Tests | 8 | 0.0 |
*Gene Silencing | 3 | 1.0 |
Prostate-Specific Antigen/biosynthesis/genetics | 3 | 50.0 |
Regulatory Sequences, Nucleic Acid | 4 | 0.0 |
Thymidine Kinase/genetics | 2 | 2.0 |
Hydrolysis | 3 | 0.0 |
Receptors, Androgen/metabolism/*physiology | 2 | 50.0 |
Transcription, Genetic/*physiology | 2 | 1.0 |
Israel | 2 | 1.0 |
Peptides | 2 | 3.0 |
Trinucleotide Repeats | 9 | 7.0 |
Prostate-Specific Antigen/*genetics | 4 | 20.0 |
Receptors, Androgen/genetics | 6 | 10.0 |
Recombinant Fusion Proteins/genetics | 2 | 1.0 |
Breast Neoplasms/*chemistry/genetics/pathology | 2 | 33.0 |
Neoplasm Invasiveness | 5 | 0.0 |
Protein p53/analysis | 3 | 1.0 |
Biopsy | 6 | 0.0 |
*Oncogene Proteins | 11 | 17.0 |
Receptors, Androgen/*biosynthesis/metabolism | 2 | 66.0 |
Immunohistochemistry/methods | 4 | 0.0 |
Karyotyping | 5 | 0.0 |
Pregnancy | 11 | 0.0 |
Australia | 2 | 1.0 |
Prostatic Neoplasms/*genetics/metabolism/pathology | 3 | 10.0 |
Regression Analysis | 5 | 0.0 |
Child | 23 | 0.0 |
Child, Preschool | 16 | 0.0 |
DNA/genetics | 7 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 11 | 0.0 |
Gene Frequency | 4 | 0.0 |
Infant | 14 | 0.0 |
Polymorphism, Genetic/*genetics | 4 | 0.0 |
Reproducibility of Results | 8 | 0.0 |
Estrogen Receptor beta | 5 | 6.0 |
Receptors, Androgen/biosynthesis/*genetics | 4 | 80.0 |
Trans-Activators/genetics | 3 | 1.0 |
Metribolone/*pharmacology | 2 | 33.0 |
Autocrine Communication/*physiology | 2 | 7.0 |
Glycoproteins/*metabolism | 5 | 2.0 |
Growth Substances/*metabolism | 4 | 2.0 |
*Intercellular Signaling Peptides and Proteins | 23 | 4.0 |
Multivariate Analysis | 5 | 0.0 |
Receptor, Epidermal Growth Factor/*metabolism | 4 | 0.0 |
Stromal Cells/metabolism | 3 | 3.0 |
Receptors, Estrogen/*analysis | 12 | 4.0 |
Receptors, Progesterone/*analysis | 7 | 3.0 |
Prostatic Neoplasms/*metabolism/pathology | 13 | 17.0 |
Chloramphenicol O-Acetyltransferase/metabolism | 3 | 2.0 |
Dimerization | 2 | 0.0 |
Prostate-Specific Antigen/*metabolism | 2 | 9.0 |
Proto-Oncogene Proteins c-jun/metabolism | 2 | 1.0 |
Carrier Proteins/metabolism | 3 | 0.0 |
Membrane Proteins/metabolism | 3 | 0.0 |
Prostatic Neoplasms/genetics/*metabolism | 4 | 14.0 |
*Saccharomyces cerevisiae Proteins | 6 | 0.0 |
Trans-Activators/metabolism | 11 | 1.0 |
Transcription Factors/metabolism | 8 | 0.0 |
Aldehyde Reductase/*metabolism | 6 | 85.0 |
*Oxidative Stress | 2 | 0.0 |
Receptors, Androgen/antagonists & inhibitors/metabolism | 2 | 66.0 |
Receptors, Androgen/*antagonists & inhibitors/genetics/metabolism | 2 | 100.0 |
Cell Survival | 4 | 0.0 |
Diabetes Complications | 2 | 1.0 |
Hydrogen Peroxide/pharmacology | 2 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 2 | 0.0 |
Muscle, Smooth, Vascular/drug effects/metabolism | 2 | 14.0 |
Phthalazines/pharmacology | 2 | 28.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Tyrphostins/pharmacology | 4 | 2.0 |
Up-Regulation/drug effects | 2 | 0.0 |
DNA/*metabolism | 7 | 1.0 |
Neurosecretory Systems/pathology | 2 | 18.0 |
Survival Rate | 8 | 0.0 |
Age of Onset | 5 | 0.0 |
Dihydrotestosterone/blood | 2 | 2.0 |
Follicle Stimulating Hormone/blood | 4 | 0.0 |
Testosterone/blood | 5 | 0.0 |
Imidazoles/pharmacology | 3 | 1.0 |
Microscopy, Fluorescence | 12 | 0.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors | 2 | 3.0 |
Pyridines/pharmacology | 2 | 0.0 |
*Up-Regulation | 2 | 0.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 2 | 0.0 |
Amino Acid Substitution | 4 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 5 | 1.0 |
Prostatic Neoplasms | 9 | 15.0 |
*Trans-Activation (Genetics)/drug effects | 3 | 7.0 |
Cell Membrane/drug effects/metabolism | 3 | 3.0 |
Estradiol/analogs & derivatives/pharmacology | 2 | 6.0 |
Estrogens/*pharmacology | 2 | 2.0 |
Receptors, Estrogen/*metabolism | 7 | 3.0 |
Tamoxifen/pharmacology | 2 | 2.0 |
Drug Synergism | 6 | 0.0 |
Ovariectomy | 3 | 2.0 |
Disease-Free Survival | 7 | 0.0 |
Receptors, Progesterone/*metabolism | 6 | 5.0 |
Drug Resistance | 4 | 0.0 |
Chromatography, High Pressure Liquid | 5 | 0.0 |
Down-Regulation/*drug effects | 2 | 3.0 |
Luciferases/genetics/metabolism | 2 | 0.0 |
Oligonucleotides, Antisense/*pharmacology | 2 | 2.0 |
Androgens/metabolism/*physiology | 5 | 100.0 |
Prostatic Neoplasms/pathology/*physiopathology | 2 | 33.0 |
Receptors, Androgen/genetics/metabolism/*physiology | 3 | 100.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Flutamide/analogs & derivatives/pharmacology | 6 | 50.0 |
Green Fluorescent Proteins | 4 | 0.0 |
*Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Severity of Illness Index | 6 | 0.0 |
Gene Amplification | 3 | 0.0 |
Gene Dosage | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 9 | 0.0 |
Dihydrotestosterone/metabolism | 7 | 12.0 |
Estrogens, Non-Steroidal/*pharmacology | 2 | 11.0 |
Luciferases/genetics | 4 | 1.0 |
Coculture Techniques | 2 | 0.0 |
Hair Follicle/metabolism | 2 | 15.0 |
Receptors, Androgen/biosynthesis | 4 | 44.0 |
Skin/cytology/metabolism | 2 | 5.0 |
Lymphatic Metastasis | 4 | 0.0 |
Sex Distribution | 2 | 0.0 |
Antineoplastic Agents, Hormonal/pharmacology | 2 | 4.0 |
DNA-Binding Proteins/genetics/*metabolism | 3 | 0.0 |
Flutamide/pharmacology | 2 | 28.0 |
Prostatic Neoplasms/drug therapy/*metabolism | 2 | 18.0 |
Protein Binding/drug effects | 2 | 0.0 |
Signal Transduction/drug effects/*physiology | 2 | 0.0 |
Trans-Activators/genetics/*metabolism | 2 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
Deoxyribonucleases, Type II Site-Specific | 2 | 0.0 |
*Dosage Compensation (Genetics) | 2 | 1.0 |
Erythrocytes/drug effects/metabolism | 2 | 14.0 |
Recombinant Proteins/genetics/metabolism | 7 | 1.0 |
Gestational Age | 6 | 0.0 |
Sequence Deletion | 8 | 0.0 |
Cell Division/physiology | 4 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects/physiology | 2 | 5.0 |
Cytoplasm/metabolism | 3 | 0.0 |
Mutagenesis | 6 | 0.0 |
Nuclear Proteins/*metabolism | 4 | 0.0 |
Transcription Factors/genetics/*metabolism | 5 | 0.0 |
*Transcription, Genetic/drug effects | 3 | 2.0 |
*Transcription Factors, TFII | 2 | 1.0 |
Carcinoma, Hepatocellular/*chemistry | 2 | 9.0 |
Liver Neoplasms/*chemistry | 2 | 8.0 |
Tumor Markers, Biological | 3 | 0.0 |
Adenine/analogs & derivatives/pharmacology | 2 | 22.0 |
Iodine Radioisotopes/diagnostic use | 3 | 0.0 |
Nitroarginine/pharmacology | 2 | 15.0 |
Norbornanes/pharmacology | 2 | 100.0 |
Receptor, Adenosine A3 | 7 | 70.0 |
Neoplasm Proteins/*analysis/genetics/physiology | 2 | 40.0 |
Prostatic Neoplasms/metabolism/*pathology | 5 | 7.0 |
Dihydrotestosterone/*metabolism | 4 | 26.0 |
Heterozygote | 3 | 0.0 |
Infant, Newborn | 9 | 0.0 |
Polymorphism, Single-Stranded Conformational | 9 | 0.0 |
Sex Hormone-Binding Globulin/metabolism | 4 | 1.0 |
Stanozolol/diagnostic use | 2 | 100.0 |
Cyclic AMP/*metabolism | 4 | 1.0 |
Androgen-Insensitivity Syndrome/*genetics | 7 | 63.0 |
*Point Mutation | 6 | 0.0 |
Testis/pathology | 3 | 6.0 |
Prostatectomy | 4 | 4.0 |
Supine Position | 2 | 9.0 |
Adenylate Cyclase/metabolism | 2 | 1.0 |
Breast Neoplasms | 4 | 1.0 |
DNA-Binding Protein, Cyclic AMP-Responsive/metabolism | 4 | 3.0 |
MAP Kinase Signaling System/physiology | 4 | 5.0 |
Promoter Regions (Genetics)/physiology | 3 | 1.0 |
Cell Culture Techniques/*methods | 2 | 2.0 |
Epitopes | 3 | 0.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Trans-Activators/*physiology | 2 | 0.0 |
DNA Methylation | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic/drug effects | 2 | 3.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Chronic Disease | 4 | 0.0 |
Questionnaires | 2 | 0.0 |
Ketoconazole/pharmacology | 2 | 2.0 |
Transcription Factors/genetics/*physiology | 2 | 1.0 |
Prostate/chemistry | 4 | 21.0 |
Rats, Sprague-Dawley | 13 | 0.0 |
Species Specificity | 5 | 0.0 |
Calcium/metabolism | 4 | 0.0 |
Drug Interactions | 5 | 0.0 |
Substrate Specificity | 5 | 0.0 |
Breast Neoplasms/genetics | 2 | 0.0 |
Culture Techniques | 2 | 0.0 |
Prostatic Neoplasms/genetics | 6 | 13.0 |
Signal Transduction/*physiology | 5 | 0.0 |
Trans-Activation (Genetics)/drug effects/physiology | 2 | 10.0 |
Transcription Factors/metabolism/pharmacology | 2 | 20.0 |
Infertility, Male/*genetics | 3 | 6.0 |
Receptors, Androgen/chemistry/*genetics/physiology | 2 | 100.0 |
Prostatic Hyperplasia/*metabolism/pathology | 3 | 10.0 |
Sulfonamides/pharmacology | 3 | 2.0 |
Acute Disease | 7 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Receptors, Androgen/*chemistry/*genetics/metabolism | 2 | 100.0 |
Androgen Antagonists/therapeutic use | 6 | 28.0 |
Receptors, Androgen/biosynthesis/genetics | 4 | 57.0 |
Receptors, Purinergic P1/agonists/*metabolism | 2 | 66.0 |
Calcium/*metabolism | 3 | 0.0 |
Cattle | 8 | 0.0 |
Nifedipine/pharmacology | 2 | 5.0 |
Spermatozoa/drug effects/*physiology | 2 | 20.0 |
Phenols/chemistry/*pharmacology | 2 | 40.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology | 3 | 2.0 |
Cyclic AMP/metabolism | 2 | 0.0 |
Transfection/genetics | 3 | 2.0 |
beta-Galactosidase/metabolism | 2 | 1.0 |
*Alleles | 2 | 0.0 |
Gene Deletion | 3 | 0.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
Rats, Long-Evans | 3 | 6.0 |
Receptors, Androgen/*biosynthesis/*genetics | 2 | 100.0 |
*Prostatectomy | 2 | 7.0 |
Cell Cycle/drug effects | 2 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Prostatic Neoplasms/*chemistry/pathology | 5 | 22.0 |
Receptors, Androgen/*drug effects/genetics/*metabolism | 2 | 100.0 |
Drug Resistance, Neoplasm | 3 | 0.0 |
Ki-67 Antigen/analysis | 5 | 1.0 |
Neoplasm Proteins/analysis | 2 | 0.0 |
Prostate/pathology | 3 | 13.0 |
Haplorhini | 5 | 1.0 |
Receptors, Androgen/chemistry/*metabolism | 4 | 80.0 |
Zinc Fingers | 3 | 0.0 |
Adenocarcinoma/*genetics | 3 | 2.0 |
Age Factors | 5 | 0.0 |
Exons/*genetics | 2 | 0.0 |
Apoptosis | 6 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 8 | 0.0 |
Prostate-Specific Antigen/analysis | 4 | 8.0 |
Receptor, Epidermal Growth Factor/metabolism | 4 | 0.0 |
Androgen Antagonists/*toxicity | 2 | 50.0 |
Cysteine Proteinase Inhibitors/pharmacology | 2 | 0.0 |
*Imidazolidines | 4 | 21.0 |
Tritium/diagnostic use | 3 | 2.0 |
Up-Regulation/*drug effects | 2 | 2.0 |
Premenopause | 2 | 2.0 |
Exons/genetics | 2 | 0.0 |
Dihydrotestosterone/metabolism/pharmacology | 2 | 50.0 |
Estradiol/metabolism/pharmacology | 3 | 23.0 |
Chloramphenicol O-Acetyltransferase/genetics | 3 | 1.0 |
Gene Expression Regulation/drug effects | 4 | 0.0 |
Organ Culture Techniques | 2 | 0.0 |
Reproduction/drug effects | 2 | 33.0 |
X Chromosome/*genetics | 2 | 0.0 |
DNA Fingerprinting | 2 | 1.0 |
Cell Cycle Proteins/*metabolism | 3 | 0.0 |
Antibodies, Monoclonal/immunology | 3 | 0.0 |
Anticarcinogenic Agents/*pharmacology | 2 | 2.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 4 | 1.0 |
Intracellular Fluid/chemistry | 2 | 13.0 |
Metribolone | 5 | 62.0 |
Stilbenes/*pharmacology | 2 | 3.0 |
Aldehyde Reductase/*chemistry/*metabolism | 2 | 100.0 |
Hydrogen Bonding | 4 | 2.0 |
Models, Molecular | 9 | 0.0 |
Protein Conformation | 12 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 3 | 0.0 |
Software | 2 | 0.0 |
Cell Count | 2 | 0.0 |
Keratin/metabolism | 2 | 1.0 |
Peptides/*genetics | 2 | 2.0 |
*X Chromosome | 7 | 0.0 |
Binding, Competitive | 15 | 0.0 |
Receptors, Purinergic P1/*antagonists & inhibitors/metabolism | 2 | 100.0 |
Receptors, Androgen/analysis/*genetics | 2 | 50.0 |
Infertility, Male/genetics | 3 | 15.0 |
Receptors, Androgen/chemistry/*genetics | 2 | 100.0 |
Androgen-Insensitivity Syndrome/genetics | 3 | 75.0 |
Sex Differentiation Disorders/*genetics | 3 | 25.0 |
Gonadal Steroid Hormones/physiology | 2 | 11.0 |
Enzyme Inhibitors/*pharmacology | 6 | 0.0 |
*DNA Methylation | 2 | 0.0 |
Metribolone/pharmacology | 5 | 21.0 |
Testosterone Congeners/pharmacology | 5 | 29.0 |
Neoplasms, Hormone-Dependent/*pathology | 3 | 16.0 |
Androgen Antagonists/pharmacology/*therapeutic use | 2 | 66.0 |
Gene Expression Regulation/*genetics | 2 | 1.0 |
Neoplasm Metastasis | 6 | 0.0 |
Prostate-Specific Antigen/*drug effects/metabolism | 2 | 100.0 |
*Antibodies, Monoclonal | 2 | 0.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Solubility | 5 | 0.0 |
Staining and Labeling/methods | 2 | 1.0 |
Receptors, Androgen/antagonists & inhibitors/genetics/*metabolism | 2 | 66.0 |
Trans-Activation (Genetics)/genetics | 6 | 6.0 |
Electric Impedance | 2 | 3.0 |
Movement/physiology | 2 | 8.0 |
Antibodies, Monoclonal | 5 | 0.0 |
Immunohistochemistry/*methods | 2 | 2.0 |
Testosterone/metabolism | 3 | 2.0 |
Aldehyde Reductase/*antagonists & inhibitors | 8 | 53.0 |
Lens, Crystalline/enzymology | 2 | 50.0 |
Rats, Wistar | 3 | 0.0 |
Recombinant Proteins | 2 | 0.0 |
Cell Proliferation | 2 | 1.0 |
*Blood Pressure | 3 | 2.0 |
*Graft Rejection | 2 | 2.0 |
*Graft Survival | 2 | 1.0 |
Kidney/*pathology | 2 | 3.0 |
*Kidney Transplantation | 2 | 0.0 |
Transplantation, Homologous | 3 | 0.0 |
DNA Footprinting | 2 | 0.0 |
DNA, Complementary/genetics | 4 | 0.0 |
Deoxyribonuclease I/genetics/metabolism | 2 | 33.0 |
Gene Expression/*drug effects | 3 | 1.0 |
Transcription Factors/genetics | 2 | 0.0 |
Heat | 4 | 0.0 |
Magnetic Resonance Spectroscopy | 4 | 0.0 |
Guinea Pigs | 4 | 0.0 |
Saccharomyces cerevisiae | 4 | 1.0 |
Plasmids | 6 | 0.0 |
Aldehyde Reductase/*blood | 3 | 100.0 |
Diabetic Nephropathies/enzymology | 2 | 40.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Prostatic Neoplasms/drug therapy/*metabolism/pathology | 2 | 33.0 |
Antineoplastic Agents, Hormonal/*pharmacology | 2 | 3.0 |
Phosphorylation/drug effects | 2 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 2 | 0.0 |
*Apoptosis | 6 | 0.0 |
Oligonucleotide Probes | 2 | 0.0 |
Receptors, Androgen/*genetics/physiology | 2 | 100.0 |
Mutation/*genetics | 5 | 0.0 |
Receptors, Glucocorticoid/metabolism | 6 | 11.0 |
Frameshift Mutation | 2 | 0.0 |
DNA, Neoplasm/metabolism | 3 | 2.0 |
Growth Substances/*biosynthesis | 2 | 4.0 |
Ki-67 Antigen/biosynthesis | 2 | 2.0 |
Orchiectomy | 11 | 10.0 |
Genetic Vectors | 5 | 0.0 |
Osmolar Concentration | 2 | 0.0 |
Testosterone/pharmacology | 7 | 11.0 |
Trans-Activation (Genetics)/physiology | 2 | 2.0 |
X Chromosome | 5 | 1.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
DNA/biosynthesis | 2 | 0.0 |
DNA Replication/drug effects | 2 | 1.0 |
RNA, Messenger/biosynthesis | 5 | 0.0 |
Transforming Growth Factor alpha/pharmacology | 2 | 2.0 |
Breast Neoplasms/genetics/*metabolism | 2 | 3.0 |
Logistic Models | 3 | 0.0 |
Odds Ratio | 4 | 0.0 |
Biological Markers/analysis | 3 | 0.0 |
Clinical Trials | 2 | 0.0 |
DNA/analysis/genetics | 2 | 1.0 |
*Exons | 4 | 1.0 |
Cell Division/genetics | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/genetics | 2 | 1.0 |
Peptides/physiology | 2 | 5.0 |
Androgens/blood | 2 | 2.0 |
Antigens, CD3/metabolism | 2 | 1.0 |
Glycoproteins/*genetics | 2 | 1.0 |
Keratin/genetics | 2 | 4.0 |
Mice, Transgenic | 7 | 0.0 |
Transcription, Genetic/drug effects | 3 | 0.0 |
DNA Replication/genetics | 2 | 3.0 |
Proteins/metabolism | 2 | 0.0 |
Prostate/*metabolism | 5 | 6.0 |
Receptors, Glucocorticoid/genetics | 2 | 14.0 |
Receptors, Estrogen/analysis | 14 | 4.0 |
Receptors, Progesterone/analysis | 10 | 4.0 |
Sex Characteristics | 5 | 0.0 |
Catalysis | 3 | 0.0 |
Tetrazolium Salts/pharmacology | 2 | 3.0 |
Thiazoles/pharmacology | 3 | 2.0 |
Skin/cytology/*metabolism | 2 | 5.0 |
Transcription, Genetic/genetics | 3 | 0.0 |
*Epidermal Growth Factor | 5 | 10.0 |
*Membrane Glycoproteins | 7 | 0.0 |
Computer Simulation | 2 | 0.0 |
Oxidation-Reduction | 3 | 0.0 |
Biological Markers | 5 | 0.0 |
Castration | 2 | 4.0 |
Neoplasms, Hormone-Dependent/genetics | 2 | 40.0 |
Exons | 9 | 0.0 |
Models, Genetic | 5 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
RNA, Messenger/*metabolism | 3 | 0.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
*Gene Expression | 5 | 0.0 |
Chromatography, Gel | 3 | 0.0 |
Tomography, Emission-Computed, Single-Photon | 2 | 3.0 |
*Immunohistochemistry | 2 | 2.0 |
Recombinant Proteins/biosynthesis | 3 | 0.0 |
Transcription Factor AP-1/*metabolism | 2 | 1.0 |
Epithelial Cells/chemistry | 2 | 5.0 |
Prostatic Hyperplasia/*metabolism | 2 | 4.0 |
Prostatic Neoplasms/*chemistry | 2 | 14.0 |
Tumor Markers, Biological/metabolism | 3 | 0.0 |
Densitometry | 3 | 2.0 |
Prostate-Specific Antigen/biosynthesis/*genetics | 2 | 66.0 |
Receptors, Androgen/*drug effects | 2 | 50.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 3 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics/metabolism | 3 | 1.0 |
Cell Line, Transformed | 4 | 0.0 |
Drug Resistance/genetics | 2 | 1.0 |
Intracellular Membranes/metabolism | 2 | 1.0 |
Syndrome | 8 | 0.0 |
Cycloheximide/pharmacology | 4 | 0.0 |
Cyproterone Acetate/pharmacology | 2 | 33.0 |
Cytoplasm/chemistry | 2 | 1.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Estradiol/*pharmacology | 2 | 0.0 |
Homeostasis | 2 | 0.0 |
Prostate/cytology/*metabolism | 2 | 18.0 |
Protein Synthesis Inhibitors/pharmacology | 4 | 1.0 |
Tamoxifen/analogs & derivatives/pharmacology | 2 | 7.0 |
PC12 Cells | 2 | 0.0 |
Receptors, Androgen/*chemistry/genetics | 2 | 100.0 |
Image Processing, Computer-Assisted | 5 | 1.0 |
Health Surveys | 2 | 2.0 |
Gene Expression Regulation, Neoplastic/*genetics | 2 | 1.0 |
Repressor Proteins/*physiology | 2 | 1.0 |
Retinoblastoma Protein/*physiology | 2 | 6.0 |
Least-Squares Analysis | 2 | 5.0 |
*Ventricular Function, Left | 2 | 15.0 |
Adrenergic beta-Agonists/*pharmacology | 2 | 9.0 |
Cell Membrane/metabolism | 5 | 0.0 |
Glycoproteins/genetics/*metabolism | 2 | 5.0 |
Glycosylation | 2 | 0.0 |
Growth Substances/genetics/*metabolism | 2 | 4.0 |
Protein Processing, Post-Translational | 3 | 0.0 |
Cytosol/chemistry | 2 | 3.0 |
Receptors, Androgen/analysis/genetics/*metabolism | 2 | 100.0 |
Temperature | 2 | 0.0 |
*Transfection | 2 | 0.0 |
Diethylstilbestrol/pharmacology | 2 | 13.0 |
*Diabetes Complications | 2 | 3.0 |
Diabetes Mellitus/*metabolism | 2 | 5.0 |
Glycoproteins/*analysis | 2 | 2.0 |
Growth Substances/*analysis | 3 | 9.0 |
Transforming Growth Factor alpha/analysis | 2 | 6.0 |
Diagnosis, Differential | 3 | 0.0 |
Organ Size | 2 | 1.0 |
Chromosome Mapping | 7 | 0.0 |
Lens, Crystalline/*enzymology | 3 | 23.0 |
Antigens, Neoplasm/analysis | 2 | 0.0 |
Breast Neoplasms/*chemistry/pathology | 4 | 6.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Receptors, Androgen/*analysis/genetics | 2 | 100.0 |
Skin/metabolism | 4 | 2.0 |
Testosterone 5-alpha-Reductase/metabolism | 2 | 28.0 |
Acrosome/*drug effects/physiology | 2 | 66.0 |
Calcimycin/*pharmacology | 2 | 6.0 |
Progesterone/*pharmacology | 3 | 3.0 |
Isoenzymes/metabolism | 3 | 0.0 |
Culture Media | 3 | 0.0 |
Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Nerve Degeneration | 2 | 3.0 |
Indicators and Reagents | 2 | 0.0 |
Heat-Shock Proteins/metabolism | 2 | 3.0 |
Receptors, Androgen/*chemistry/genetics/metabolism | 2 | 100.0 |
Forced Expiratory Volume/drug effects | 2 | 9.0 |
RNA, Messenger/analysis/genetics | 3 | 0.0 |
Staining and Labeling | 5 | 0.0 |
Receptors, Purinergic P1/*genetics/metabolism | 2 | 100.0 |
Active Transport, Cell Nucleus/physiology | 2 | 3.0 |
Macromolecular Substances | 3 | 0.0 |
Receptors, Androgen/*chemistry | 3 | 75.0 |
DNA/analysis | 2 | 0.0 |
Follicular Fluid/*physiology | 2 | 40.0 |
Carcinogens/pharmacology | 3 | 3.0 |
Plant Extracts/*pharmacology | 2 | 2.0 |
Genes, Recessive | 2 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Acrosome/*physiology | 4 | 50.0 |
*Sperm-Ovum Interactions | 2 | 10.0 |
Zona Pellucida/*physiology | 4 | 25.0 |
Bucladesine/pharmacology | 2 | 1.0 |
Chloramphenicol O-Acetyltransferase/biosynthesis | 3 | 2.0 |
Androgens/*metabolism/pharmacology | 2 | 40.0 |
RNA, Messenger/drug effects | 2 | 3.0 |
*Genes, Reporter | 2 | 4.0 |
Fertilization in Vitro | 2 | 1.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
Epithelium/metabolism | 2 | 0.0 |
Aldehyde Reductase/*antagonists & inhibitors/metabolism | 2 | 100.0 |
Imidazoles/*chemical synthesis/chemistry/pharmacology | 2 | 66.0 |
Fungal Proteins/biosynthesis | 2 | 14.0 |
Receptors, Androgen/biosynthesis/chemistry/*metabolism | 2 | 100.0 |
Codon | 3 | 0.0 |
Prostatic Neoplasms/*genetics/physiopathology | 2 | 66.0 |
Sorbitol/metabolism | 4 | 33.0 |
Centrifugation, Density Gradient | 4 | 1.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Cytosol/metabolism | 9 | 1.0 |
Gene Amplification/*genetics | 2 | 1.0 |
Neoplasm Recurrence, Local/genetics | 3 | 14.0 |
Treatment Failure | 3 | 1.0 |
Recombinant Fusion Proteins | 2 | 0.0 |
Androgens/deficiency/physiology | 2 | 100.0 |
Genes, Tumor Suppressor | 2 | 0.0 |
Prostate-Specific Antigen | 2 | 1.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Follow-Up Studies | 6 | 0.0 |
*Gene Amplification | 4 | 1.0 |
Receptors, Adrenergic, beta/*metabolism | 2 | 11.0 |
Ploidies | 3 | 1.0 |
Kidney/cytology/drug effects/metabolism | 2 | 10.0 |
RNA Interference | 5 | 1.0 |
Gene Expression Regulation, Neoplastic/physiology | 2 | 1.0 |
Hyperplasia | 2 | 0.0 |
Androgen-Binding Protein/genetics | 2 | 66.0 |
Cell Extracts | 2 | 1.0 |
Escherichia coli/genetics | 2 | 0.0 |
Luciferases/biosynthesis | 2 | 2.0 |
Dyes | 2 | 1.0 |
Neoplasms, Hormone-Dependent/*chemistry/pathology | 3 | 60.0 |
Microwaves | 2 | 8.0 |
Cytomegalovirus/genetics | 2 | 2.0 |
*Fertilization in Vitro | 2 | 1.0 |
Prostatic Neoplasms/genetics/metabolism/*pathology | 4 | 40.0 |
Fetus | 2 | 0.0 |
Receptors, Androgen/*drug effects/*physiology | 2 | 100.0 |
Drug Therapy, Combination | 2 | 0.0 |
Steroids/*pharmacology | 2 | 10.0 |
Receptor, Epidermal Growth Factor/*analysis | 3 | 0.0 |
Lymph Nodes/*metabolism/pathology | 2 | 20.0 |
Oncogenes | 2 | 0.0 |
Lung Neoplasms | 2 | 1.0 |
Protein p53/metabolism | 3 | 0.0 |
Proto-Oncogene Proteins/metabolism | 4 | 0.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
RNA, Messenger/*analysis | 3 | 0.0 |
Enzyme Induction | 2 | 0.0 |
Kidney | 2 | 0.0 |
Antibodies | 3 | 0.0 |
Formaldehyde | 2 | 2.0 |
Paraffin | 2 | 4.0 |
Charcoal | 2 | 7.0 |
Ovarian Follicle/*chemistry | 2 | 50.0 |
Graft Rejection/*diagnosis | 2 | 28.0 |
1-(5-Isoquinolinesulfonyl)-2-methylpiperazine | 2 | 3.0 |
Isoquinolines/pharmacology | 3 | 2.0 |
Piperazines/pharmacology | 2 | 1.0 |
Receptors, Androgen/*agonists/*antagonists & inhibitors/metabolism | 2 | 100.0 |
Microscopy, Electron | 3 | 0.0 |
Chemotherapy, Adjuvant | 3 | 1.0 |
Radioimmunoassay | 3 | 0.0 |
Epidermal Growth Factor/metabolism | 2 | 0.0 |
Electrocardiography | 2 | 0.0 |
*Models, Cardiovascular | 2 | 6.0 |
Buffers | 2 | 1.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
*Heart Rate | 3 | 6.0 |
DNA | 2 | 0.0 |
Swine | 5 | 0.0 |
Regulatory Sequences, Nucleic Acid/*genetics | 2 | 2.0 |
Restriction Mapping | 4 | 0.0 |
Lymphatic Metastasis/*pathology | 2 | 5.0 |
Liver/*chemistry | 2 | 5.0 |
Tamoxifen/*therapeutic use | 2 | 2.0 |
Stereoisomerism | 3 | 0.0 |
*Bronchial Provocation Tests | 2 | 18.0 |
Methacholine Chloride/diagnostic use | 2 | 11.0 |
Skin Tests | 2 | 1.0 |
Peptide Fragments/analysis | 2 | 0.0 |
Neural Conduction/drug effects | 3 | 23.0 |
Tritium | 2 | 0.0 |
Molecular Biology | 2 | 0.0 |
Lymph Nodes/pathology | 2 | 0.0 |
Aldehyde Reductase/*analysis | 2 | 100.0 |
Retina/*enzymology | 2 | 22.0 |
Frozen Sections | 2 | 2.0 |
Mifepristone/pharmacology | 3 | 3.0 |
Cell Movement/drug effects | 2 | 0.0 |
Dinoprostone/*pharmacology | 2 | 3.0 |
Prostaglandin-Endoperoxide Synthase/metabolism | 2 | 2.0 |
Diabetic Neuropathies/*drug therapy | 2 | 40.0 |
*Response Elements | 2 | 3.0 |
Cell Division/drug effects/physiology | 3 | 1.0 |
Microsomes/enzymology | 2 | 1.0 |
Microscopy, Confocal | 2 | 0.0 |
Chromosomes, Human, X/*genetics | 2 | 6.0 |
Skin/*chemistry | 2 | 6.0 |
Isoproterenol/*pharmacology | 2 | 13.0 |
Glycoproteins/*analysis/genetics | 2 | 40.0 |
Neoplasm Proteins/*analysis/genetics | 2 | 4.0 |
Isoelectric Focusing | 2 | 0.0 |
Receptors, Steroid/*analysis | 9 | 37.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
Rats, Inbred Strains | 7 | 0.0 |
Seminal Vesicles/drug effects/*metabolism/ultrastructure | 2 | 100.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Prostatic Neoplasms/drug therapy/genetics/*metabolism | 2 | 40.0 |
Erythrocytes/*enzymology | 3 | 0.0 |
ROC Curve | 2 | 1.0 |
Posture | 2 | 2.0 |
Renin/*blood | 3 | 3.0 |
Skin/cytology | 2 | 1.0 |
Electroencephalography | 3 | 1.0 |
Androgens/pharmacology/physiology | 2 | 100.0 |
Progesterone/biosynthesis | 2 | 4.0 |
Receptors, Androgen/analysis/*metabolism | 2 | 100.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Autoradiography | 2 | 0.0 |
Neoplasms, Hormone-Dependent/*metabolism/pathology | 2 | 40.0 |
Testosterone Congeners/metabolism | 2 | 40.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Cytosol/analysis | 4 | 12.0 |
Stroke Volume | 2 | 3.0 |
Hydrophobicity | 2 | 2.0 |
Androgens/*blood | 3 | 2.0 |
*Genes, Structural | 2 | 0.0 |
*Disease Models, Animal | 2 | 0.0 |
Trinucleotide Repeat Expansion/*genetics | 2 | 3.0 |
Androgens/*analysis | 2 | 40.0 |
Dihydrotestosterone/analysis | 2 | 40.0 |
Prostate/*analysis | 3 | 50.0 |
Testosterone/analysis | 2 | 18.0 |
Cell Separation | 2 | 0.0 |
Androgen-Insensitivity Syndrome/genetics/metabolism | 2 | 100.0 |
Receptor Cross-Talk | 2 | 5.0 |
Receptors, Androgen/*analysis/metabolism | 2 | 100.0 |
Spermatozoa/*physiology | 2 | 5.0 |
Receptors, Androgen/*antagonists & inhibitors | 2 | 100.0 |
Neoplasms, Hormone-Dependent/*analysis | 2 | 50.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Prostatic Hyperplasia/*pathology | 2 | 10.0 |
*Electrocardiography | 2 | 3.0 |
Long-Term Care | 2 | 3.0 |
Menopause | 2 | 0.0 |
Chromatin/genetics/metabolism | 2 | 6.0 |
Sugar Alcohol Dehydrogenases/*metabolism | 2 | 40.0 |
DNA-Binding Proteins/*genetics/metabolism | 2 | 0.0 |
Cardiac Output | 2 | 4.0 |
Estrenes/metabolism | 3 | 60.0 |
Dexamethasone/metabolism | 2 | 12.0 |
Receptors, Glucocorticoid/analysis | 2 | 50.0 |
Cytoplasm/analysis | 2 | 9.0 |
Sex Chromosome Aberrations/*diagnosis | 2 | 33.0 |
Prostate/physiology | 2 | 16.0 |
*Genes, BRCA1 | 2 | 0.0 |
*Genes, BRCA2 | 2 | 0.0 |
Prostaglandins/physiology | 2 | 11.0 |
Androgen Antagonists/*metabolism | 2 | 50.0 |
Proteasome Endopeptidase Complex | 3 | 0.0 |
Quinones/pharmacology | 2 | 1.0 |
Cysteine Endopeptidases/*metabolism | 2 | 0.0 |
Multienzyme Complexes/*metabolism | 2 | 1.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Drug Design | 2 | 0.0 |
